Cell And Gene Therapy Clinical Milestones Highlight Reimbursement Challenges
This article was originally published in Scrip
Executive Summary
The Stem Cell Meeting on the Mesa began on Oct. 7 in San Diego just a few days after Spark Therapeutics posted positive Phase III results that could support the first-ever US FDA approval of a gene therapy, but the achievement and the conference highlighted a still-unsolved challenge for regenerative medicines: How will health care systems pay for curative, one-time treatments?